Reassessing AbCellera Biologics (ABCL) After A Sharp 16.8% Weekly Share Price Drop [Yahoo! Finance]
AbCellera Biologics Inc. - Common Shares (ABCL)
Company Research
Source: Yahoo! Finance
If you are wondering whether AbCellera Biologics shares are priced attractively today, this article walks through what the current market price might be suggesting about value. The stock last closed at US$3.86, after a 16.8% decline over the past 7 days, while returns over 30 days, year to date, and the last year are 11.9%, 12.5%, and 19.5% respectively. This compares with a 64.9% decline over 3 years and a 91.7% decline over 5 years. Recent price moves sit against an ongoing investor focus on AbCellera Biologics as a drug discovery and development business. Sentiment can shift quickly as the market reassesses long term potential and risk, and these swings often lead investors to reconsider whether the current share price lines up with expectations for the company. On our valuation checks, AbCellera Biologics scores 2 out of 6 . We will unpack this using several common valuation approaches before coming back to a more complete way of thinking about value at the end of the artic
Show less
Read more
Impact Snapshot
Event Time:
ABCL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ABCL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABCL alerts
High impacting AbCellera Biologics Inc. - Common Shares news events
Weekly update
A roundup of the hottest topics
ABCL
News
- AbCellera to Report Full Year 2025 Financial Results on February 24, 2026Business Wire
- AbCellera Biologics (NASDAQ:ABCL) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=ABCL&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StrMarketBeat
- AbCellera Biologics Pivots to Internal Pipeline at JPMorgan, Teases Key Milestones for 2026 [Yahoo! Finance]Yahoo! Finance
- AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause [Yahoo! Finance]Yahoo! Finance
- AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to MenopauseBusiness Wire
ABCL
Earnings
- 11/6/25 - Miss
ABCL
Sec Filings
- 1/14/26 - Form 8-K
- 1/5/26 - Form 4
- 1/5/26 - Form 4
- ABCL's page on the SEC website